| Gregory Jarrin, MD | |
|
500 Indiana Ave, Winslow, AZ 86047-2169 | |
| (928) 289-4646 | |
| (928) 289-6290 |
| Full Name | Gregory Jarrin |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 35 Years |
| Location | 500 Indiana Ave, Winslow, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275663197 | NPI | - | NPPES |
| P00468244 | Other | AZ | RAILROAD MEDICARE |
| 437683 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 30338 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Whiteriver Phs Indian Hospital | Whiteriver, AZ | Hospital |
| Summit Healthcare Regional Medical Center | Show low, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Ihs Phoenix Area | 2668649567 | 63 |
News Archive
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.
› Verified 2 days ago
| Entity Name | Tuba City Regional Health Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548294424 PECOS PAC ID: 4284542531 Enrollment ID: O20031105000107 |
News Archive
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.
› Verified 2 days ago
| Entity Name | Winslow Indian Health Care Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184729493 PECOS PAC ID: 4284548991 Enrollment ID: O20031117000864 |
News Archive
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.
› Verified 2 days ago
| Entity Name | Dhhs Ihs Phoenix Area |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427335140 PECOS PAC ID: 2668649567 Enrollment ID: O20120117000781 |
News Archive
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory Jarrin, MD 500 Indiana Ave, Winslow, AZ 86047-2169 Ph: (928) 289-4646 | Gregory Jarrin, MD 500 Indiana Ave, Winslow, AZ 86047-2169 Ph: (928) 289-4646 |
News Archive
New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.
People who walk to work are around 40 per cent less likely to have diabetes as those who drive, according to a new study.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
An international vaccine symposium sponsored by the University of Texas Medical Branch at Galveston and scheduled for Feb. 7-9 will reflect a dramatic shift in the world of vaccinology, according to Alan Barrett, director of UTMB's Sealy Center for Vaccine Development.
› Verified 2 days ago
Dr. Rishi Tejas Dholakia, DO, MPH Surgery Medicare: Accepting Medicare Assignments Practice Location: 500 Indiana Ave, Winslow, AZ 86047 Phone: 928-289-4646 | |
Dilip K Parikh, M.D Surgery Medicare: Medicare Enrolled Practice Location: 200 East Lee Street, Winslow, AZ 86047 Phone: 928-289-3396 Fax: 928-289-2801 | |
Brian A Bucina, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 Lee St, Winslow, AZ 86047 Phone: 928-289-3396 Fax: 928-289-2801 |